GL-7190 is under clinical development by Gliknik and currently in Phase I for Autoimmune Disorders. According to GlobalData, Phase I drugs for Autoimmune Disorders have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GL-7190’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GL-7190 overview
GL-7190 is under development for the treatment of immunological disorders, acute intravascular hemolysis, glomerulonephritis, Heymann nephritis. It acts by targeting C1q.
Gliknik overview
Gliknik is a biopharmaceutical company that develops therapies for immune disorders. The company involves in the discovery and clinical development of drugs, with a focus on recombinant fusion proteins. Its pipeline products are developed to simulate effects of the pooled human blood product intravenous immunoglobulin, for treating autoimmune diseases. It also develops drugs for treating oral cavity cancer. The company operates across the US. Gliknik is headquartered in Baltimore, Maryland, the US.
For a complete picture of GL-7190’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
